Your browser doesn't support javascript.
loading
Safety of the Immediate Reconstitution of Poly-l-Lactic Acid for Facial and Body Treatment-A Multicenter Retrospective Study.
Vasconcelos-Berg, Roberta; Real, Julia; Wenz, Franziska; Avelar, Luiz Eduardo Toledo.
Afiliación
  • Vasconcelos-Berg R; Margarethenklinik, University Hospital of Basel, Basel, Switzerland.
  • Real J; Private Practice, Belo Horizonte, Brazil.
  • Wenz F; Margarethenklinik, University Hospital of Basel, Basel, Switzerland.
  • Avelar LET; Private Practice, Belo Horizonte, Brazil.
J Cosmet Dermatol ; 2024 Sep 17.
Article en En | MEDLINE | ID: mdl-39285829
ABSTRACT

BACKGROUND:

Poly-l-lactic acid (PLLA-SCA; Sculptra) was approved in 1999 in Europe and 2004 in United States as a collagen biostimulator. It is a freeze-dried preparation containing 150 mg PLLA-SCA per vial and, since approval, has been recommended to be reconstituted 72 h before treatment, which can hinder its use in clinical practice. In 2021, the manufacturer authorized the reconstitution of PLLA-SCA immediately before use.

OBJECTIVE:

To evaluate adverse events in patients treated with immediately reconstituted PLLA-SCA on the face, body, and scars.

METHOD:

This was a retrospective analysis of medical records of patients treated with immediately reconstituted PLLA-SCA for aesthetic purposes from January 1, 2021, to December 31, 2021, at two medical centers.

RESULTS:

A total of 274 treatment sessions were conducted on 167 patients (ranging from 1 to 5 sessions per patient). Of these, 228 sessions (151 patients) targeted the face, 39 sessions (22 patients) addressed the body, and 7 sessions (5 patients) focused on scars. The mean final concentration of PLLA-SCA was 15.30 mg/mL for the face, 8.35 mg/mL for the body, and 10.53 mg/mL for scars. The majority of injections were administered with a blunt cannula (face 87.3%, body 100%, scars 57%), and in 6 out of 7 scar treatments, PLLA-SCA was additionally applied topically after fractional treatment. One patient developed a PLLA-SCA nodule 30 days after facial treatment, which resolved after two saline injections. The most common adverse events were bruising (face 6.57%, body 7.69%) and mild pain (face 3.07%). No events required further intervention.

CONCLUSION:

This study reports an adverse event profile with immediately reconstituted PLLA-SCA, used on the face, body, and scars, similar to that reported with PLLA-SCA reconstituted 72 h prior to use. TRIAL REGISTRATION This was a retrospective study of medical records at two medical centers, and trial registration was not required.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Cosmet Dermatol Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Cosmet Dermatol Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Reino Unido